Biospecimen and Pathology Core

生物样本和病理学核心

• 批准号: 10473658
• 负责人: CARL D MORRISON
• 金额: $ 9.86万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-18 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10473658
• 关键词: American; American Society of Clinical Oncology; Archives; Biological Assay; Blood specimen; Clinical; Clinical Research; Clinical Trials; Collection; Coupled; Cytometry; DNA methylation profiling; Data; Diagnostic; Drug or chemical Tissue Distribution; Eligibility Determination; Evaluation; Experimental Designs; Guidelines; Histologic; Histology; Histopathology; Human; Human Resources; Image; Immune; Immunogenomics; Immunohistochemistry; Immunologics; Individual; Informatics; Infrastructure; Ischemia; Malignant neoplasm of ovary; Pathologic; Pathologist; Pathology; Patients; Performance; Phenotype; Preparation; Process; Protocols documentation; Quality Control; Research Personnel; Research Project Grants; Research Support; Sampling; Scanning; Services; Site; Slide; Specimen; Standardization; T cell receptor repertoire sequencing; Testing; Time; Tissue Microarray; Tissues; Training; Translational Research; Tumor Tissue; Tumor-Infiltrating Lymphocytes; automated image analysis; base; biobank; college; data dissemination; digital; digital imaging; exome sequencing; experience; immunological status; informatics infrastructure; interest; laser capture microdissection; next generation sequencing; ovarian neoplasm; sample fixation; tissue resource; tool; transcriptome sequencing; tumor; tumor microenvironment

ABSTRACT The Roswell Park Ovarian Cancer SPORE Biospecimen & Pathology Core (BPC) combines a centralized mechanism for expert tissue handling services and performance of tissue-based assays by highly qualified, experienced personnel with a state-of-the-art integrated informatics infrastructure which provides tools for tracking biospecimen collection, histopathological evaluation, and clinical annotation of samples with linkage to immunogenomic and other translational data generated by the Individual Research Projects proposed in this renewal application. The Core will collect, de-identify, process, bank, and distribute annotated, high-quality tumor and blood samples from patients participating in SPORE-sponsored clinical studies. In addition, the BPC will provide investigators with specialized technical and interpretative histopathology services including expertise in multiplexed immunohistochemistry (IHC) and imaging mass cytometry (IMC), tissue microarray construction, laser capture microdissection, digital imaging, and quantitative pathology review of slides, tumor- infiltrating lymphocytes assessment, tissue QC/QA and preparation for next-gen sequencing-based assays (whole exome seq, RNAseq, TCRseq, MethylSEQ), and oversight on optimal utilization of each biospecimen. The Core will also be instrumental in testing patient biospecimens to determine eligibility for clinical trials and directly add to the bi-directional translational science by a detailed immunological annotation of ovarian tumors.

抽象的 罗斯威尔公园卵巢癌 SPORE 生物样本和病理学核心 (BPC) 结合了集中式 专家组织处理服务和组织检测性能的机制，由高素质的、 经验丰富的人员，拥有最先进的综合信息学基础设施，为 跟踪生物样本采集、组织病理学评估和样本的临床注释 本报告中提出的个人研究项目生成的免疫基因组和其他转化数据 续订申请。核心将收集、去识别、处理、存储和分发带注释的高质量 来自参加 SPORE 赞助的临床研究的患者的肿瘤和血液样本。此外，BPC 将为研究人员提供专门的技术和解释性组织病理学服务，包括 多重免疫组织化学 (IHC) 和成像质量流式细胞仪 (IMC)、组织微阵列方面的专业知识 构建、激光捕获显微切割、数字成像和载玻片的定量病理学审查、肿瘤- 浸润淋巴细胞评估、组织 QC/QA 以及下一代测序检测的准备 （全外显子组序列、RNAseq、TCRseq、MmethylSEQ），并监督每个生物样本的最佳利用。 该核心还将有助于测试患者生物样本，以确定临床试验的资格和 通过卵巢肿瘤的详细免疫学注释直接添加到双向转化科学。